These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37473965)

  • 1. Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? A state-of-the-art review.
    Zhang Z; Zhu L; Wang Z; Hua N; Hu S; Chen Y
    Prog Lipid Res; 2023 Jul; 91():101240. PubMed ID: 37473965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence.
    Shabir K; Brown JE; Afzal I; Gharanei S; Weickert MO; Barber TM; Kyrou I; Randeva HS
    Cytokine Growth Factor Rev; 2021 Aug; 60():120-132. PubMed ID: 34108103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein tyrosine phosphatase receptor δ serves as the orexigenic asprosin receptor.
    Mishra I; Xie WR; Bournat JC; He Y; Wang C; Silva ES; Liu H; Ku Z; Chen Y; Erokwu BO; Jia P; Zhao Z; An Z; Flask CA; He Y; Xu Y; Chopra AR
    Cell Metab; 2022 Apr; 34(4):549-563.e8. PubMed ID: 35298903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects.
    Farrag M; Ait Eldjoudi D; González-Rodríguez M; Cordero-Barreal A; Ruiz-Fernández C; Capuozzo M; González-Gay MA; Mera A; Lago F; Soffar A; Essawy A; Pino J; Farrag Y; Gualillo O
    Front Endocrinol (Lausanne); 2022; 13():1101091. PubMed ID: 36686442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asprosin-A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature.
    Mazur-Bialy AI
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33673009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrillin-1 and asprosin, novel players in metabolic syndrome.
    Summers KM; Bush SJ; Davis MR; Hume DA; Keshvari S; West JA
    Mol Genet Metab; 2023 Jan; 138(1):106979. PubMed ID: 36630758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases.
    Li X; Liao M; Shen R; Zhang L; Hu H; Wu J; Wang X; Qu H; Guo S; Long M; Zheng H
    Mediators Inflamm; 2018; 2018():7375294. PubMed ID: 30524197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Energy Regulation Mechanism and Therapeutic Potential of Asprosin.
    Hoffmann JG; Xie W; Chopra AR
    Diabetes; 2020 Apr; 69(4):559-566. PubMed ID: 32198197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion.
    Wang Y; Qu H; Xiong X; Qiu Y; Liao Y; Chen Y; Zheng Y; Zheng H
    Mediators Inflamm; 2018; 2018():9471583. PubMed ID: 29743813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome.
    Deniz R; Yavuzkir S; Ugur K; Ustebay DU; Baykus Y; Ustebay S; Aydin S
    J Obstet Gynaecol; 2021 Feb; 41(2):279-284. PubMed ID: 32608281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased Circulating Levels of Asprosin in Obese Children.
    Long W; Xie X; Du C; Zhao Y; Zhang C; Zhan D; Li Z; Ning Q; Luo X
    Horm Res Paediatr; 2019; 91(4):271-277. PubMed ID: 31212299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asprosin: A Novel Player in Metabolic Diseases.
    Yuan M; Li W; Zhu Y; Yu B; Wu J
    Front Endocrinol (Lausanne); 2020; 11():64. PubMed ID: 32153505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel adipokine asprosin modulates browning and adipogenesis in white adipose tissue.
    Miao Y; Qin H; Zhong Y; Huang K; Rao C
    J Endocrinol; 2021 May; 249(2):83-93. PubMed ID: 33705351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asprosin-neutralizing antibodies as a treatment for metabolic syndrome.
    Mishra I; Duerrschmid C; Ku Z; He Y; Xie W; Silva ES; Hoffman J; Xin W; Zhang N; Xu Y; An Z; Chopra AR
    Elife; 2021 Apr; 10():. PubMed ID: 33904407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and purification of asprosin in Pichia pastoris and investigation of its increase glucose uptake activity in skeletal muscle through activation of AMPK.
    Zhang Y; Zhu Z; Zhai W; Bi Y; Yin Y; Zhang W
    Enzyme Microb Technol; 2021 Mar; 144():109737. PubMed ID: 33541572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased plasma asprosin levels in patients with drug-naive anorexia nervosa.
    Hu Y; Xu Y; Zheng Y; Kang Q; Lou Z; Liu Q; Chen H; Ji Y; Guo L; Chen C; Ruan L; Chen J
    Eat Weight Disord; 2021 Feb; 26(1):313-321. PubMed ID: 32026376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression and ELISA-based detection of asprosin in cultured cells and mice.
    Mishra I; Chopra AR
    STAR Protoc; 2022 Dec; 3(4):101762. PubMed ID: 36240062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients.
    Chang CL; Huang SY; Hsu YC; Chin TH; Soong YK
    Sci Rep; 2019 Apr; 9(1):6447. PubMed ID: 31015585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum circulating asprosin levels in children with obesity.
    Sünnetçi Silistre E; Hatipoğl HU
    Pediatr Int; 2020 Apr; 62(4):467-476. PubMed ID: 32003085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin.
    Li E; Shan H; Chen L; Long A; Zhang Y; Liu Y; Jia L; Wei F; Han J; Li T; Liu X; Deng H; Wang Y
    Cell Metab; 2019 Aug; 30(2):319-328.e8. PubMed ID: 31230984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.